Spots Global Cancer Trial Database for Expanded Access to Ensartinib for Participants With ALK+ NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Expanded Access to Ensartinib for Participants With ALK+ NSCLC
Official Title: Expanded Access Intermediate-Size Patient Population Protocol
Study ID: NCT04146571
Interventions
Study Description
Brief Summary: This is an open-label, multicenter, intermediate-sized expanded access treatment protocol to the existing IND 111,695 for ensartinib (X-396). The treatment plan is designed to provide ensartinib to participants with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).
Detailed Description: Open-label, multi-center, intermediate-sized expanded access treatment protocol for X396-CLI-101 (Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer)
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford University, Stanford, California, United States
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
Vanderbilt University, Nashville, Tennessee, United States
University of Wisconsin Carbone Cancer Ctr, Madison, Wisconsin, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
